10th Translational Research Conference
Myeloproliferative Neoplasms
April 26-28, 2024 – Mandelieu-La Napoule, France
Chairpersons: Jean-Jacques Kiladjian, Ross L. Levine, Jyoti Nangalia

Friday, April 26th, 2024

08:30-08:40 Welcome: Jean-Jacques Kiladjian, Jyoti Nangalia

SESSION I – Molecular pathogenesis of MPNs
Chair: Jean-Jacques Kiladjian (Paris)

08:40-08:45	Introduction	Jean-Jacques Kiladjian (Paris)
08:45-09:15	**Keynote Lecture** MPN pathogenesis – a riddle wrapped in a mystery inside an enigma	Anthony Green (Cambridge)
09:15-09:25	*Discussion*	
09:25-09:40	Evolution of clonal hematopoiesis to MPN	Gerwin Huls (Groningen)
09:40-09:45	*Discussion*	
09:45-10:00	Insights from Genomic Studies of MPN	Jyoti Nangalia (Cambridge)
10:00-10:05	*Discussion*	
10:05-10:35	*Panel discussion*	
10:35-11:05	***Coffee Break***	

SESSION II – Novel MPN therapeutic targets
Chair: Shannon Elf (Salt Lake City)

11:05-11:10	Introduction	Shannon Elf (Salt Lake City)
11:10-11:25	Targeting Inflammation in MPN	Angela Fleischman (Irvine)
11:25-11:30	*Discussion*	
11:30-11:45	Targeting iron metabolism in MPN	Ronald Hoffman (New York)
11:45-11:50	*Discussion*	
11:50-11:57	Brief oral communication *Soluble forms of the thrombopoietin receptor as novel therapeutic options in MPNs*	Audrey Nédélec (Brussels)
11:57-12:00	*Discussion*	

12:00-12:30	*Panel discussion*	
12:30-14:25	***Lunch***	

13:15-14:15 **SATELLITE SYMPOSIUM**

Myelofibrosis: are we entering a new era?

Chair: Claire Harrison (London)

Speakers: Claire Harrison (London), Alessandro M. Vannucchi (Florence), Haifa Kathrin Al-Ali (Halle)

This symposium is organized and sponsored by Stemline, a Menarini Group Company

SESSION III – MPN clonal evolution
Chair: Claire Harrison (London)

14:25-14:30	Introduction	Claire Harrison (London)
14:30-14:45	Prognostic impact of molecular landscape in 428 polycythemia vera from the French MPN database (fimbank)	Damien Luque Paz (Angers)
14:45-14:50	*Discussion*	
14:50-15:05	Unmasking MPN transformation paths	Lina Benajiba (Paris)
15:05-15:10	*Discussion*	
15:10-15:17	Brief oral communication *The natural history and clonal evolution of myeloproliferative neoplasms during clinical therapy*	Daniel Leongamornlert (Hinxton)
15:17-15:20	*Discussion*	
15:20-15:35	Molecular pathogenesis to leukaemic transformation	Adam Mead (Oxford)
15:35-15:40	*Discussion*	
15:40-15:55	Mechanisms of leukemic transformation in MPNs	Raajit Rampal (New York)
15:55-16:00	*Discussion*	
16:00-16:25	*Panel discussion*	
16:25-16:50	***Coffee break***	

SESSION IV – MPN models and pathogenesis/therapeutic studies
Chair(s): Andreas Reiter (Mannheim)

16:50-16:55	Introduction	Andreas Reiter (Mannheim)
16:55-17:10	Ex vivo modeling of MPN	Beth Psaila (Oxford)
17:10-17:15	*Discussion*	
17:15-17:30	Novel approaches to modeling MPN	Grant Challen (St. Louis)
17:30-17:35	*Discussion*	

17:35-17:50	Immunothrombosis: a major actor of MPN-associated thrombosis	Chloé James (Bordeaux)
17:50-17:55	*Discussion*	
17:55-18:10	The conundrum of TP53 mutations in MPN	Ann Mullally (Boston)
18:10-18:15	*Discussion*	
18:15-18:22	Brief oral communication *Maintenance of haematopoietic stem cells by tyrosine-unphosphorylated STAT5 and JAK inhibition*	Matthew Williams (Cambridge)
18:22-18:25	*Discussion*	
18:25-18:55	*Panel discussion*	

19:00-20:00 **Mentored Poster Walks and Welcome Get-Together stand-up buffet dinner**

- *Biology Poster Walk Leaders: Shannon Elf* (Salt Lake City)*, Stephen Oh (St Louis)*
- *Clinical Poster Walk Leaders: Claire Harrison (London), Ruben Mesa* (Charlotte)

Saturday, April 27th, 2024

07:50-08:50 **3 Simultaneous Meet the Expert sessions**

1.	Novel therapies for mastocytosis	Andreas Reiter (Mannheim)
2.	Novel therapies for MPN	John Mascarenhas (New York)
3.	Novel MPN preclinical models	Grant Challen (St Louis)

09:00-10:00 **SATELLITE SYMPOSIUM**

Raising the Bar in Myelofibrosis

Chair: Claire Harrison (London)

Speakers: Alessandro M. Vannucchi (Florence), Claire Harrison (London), John Mascarenas (New York)

This symposium is organized and sponsored by GSK

10:00-10:30 ***Coffee break***

SESSION V – New therapies and challenges in the management of MPN
Chair: John Mascarenhas (New York)

10:30-10:35	Introduction	John Mascarenhas (New York)
10:35-10:50	Novel Therapies for High Risk MPN	Prithviraj Bose (Houston)
10:50-10:55	*Discussion*	
10:55-11:10	How to recognize and manage ruxolitinib treatment failure?	Alessandro Vannucchi (Florence)
11:10-11:15	*Discussion*	
11:15-11:30	Role of inflammatory signaling in MPN pathogenesis and therapeutic response	Stephen Oh (St Louis)
11:30-11:35	*Discussion*	

11:35-11:42	Brief oral communication *Type 2 but not type 1 calreticulin mutations upregulate a targetable ATF6/BCL-xL pathway in myeloproliferative neoplasms*	Nicole Arellano (Salt Lake City)
11:42-11:45	*Discussion*	
11:45-12:15	*Panel discussion*	
12:15-14:10	***Lunch***	

SESSION VI – Update on therapeutic approaches in MPN
Chair(s): Raajit Rampal (New York)

14:10-14:15	Introduction	Raajit Rampal (New York)
14:15-14:30	Advances and remaining gaps in the treatment of MPNs	Ruben Mesa (Charlotte)
14:30-14:35	*Discussion*	
14:35 -14:50	Novel MPN Therapeutics	Ross L. Levine (New York)
14:50-14:55	*Discussion*	
14:55-15:02	Brief oral communication *Pelabresib in combination with ruxolitinib for janus kinase inhibitor treatment-naïve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study*	Raajit Rampal (New-York)
15:02 -15:05	*Discussion*	
15:05 -15:35	*Panel discussion*	
15:35-16:05	***Coffee break***	

SESSION VII – Update in MPN diagnostics
Chair(s): Beth Psaila (Oxford)

16:05-16:10	Introduction	Beth Psaila (Oxford)
16:10-16:25	Real world investigation and diagnosis of triple negative thrombocytosis	Anna Godfrey (Cambridge)
16:25-16:30	*Discussion*	
16:30-16:45	Machine learning for MPN diagnostics	Dan Royston (Oxford)
16:45-16:50	*Discussion*	
16:50-17:05	MPN/MDS overlap: new criteria and current management	Lionel Adès (Paris)
17:05-17:10	*Discussion*	
17:10-17:17	Brief oral communication *Spatial profiling of bone marrow vascular niche in myeloproliferative neoplasms patients*	Jimena Castorena (Villejuif)
17:17-17:20	*Discussion*	
17:20-17:50	*Panel discussion*	

Sunday, April 28th, 2024

07:30-08:30 3 Simultaneous Breakfast Meet the Expert Sessions

1. Emerging clinical trial concepts in MPNs	Claire Harrison (London)
2. MPN microenvironment including aberrant megakaryocytes on MF pathogenesis	Angela Fleischman (Irvine), Beth Psaila (Oxford)
3. Guidelines and gaps in MPNs	Ruben Mesa (Charlotte), Jean-Jacques Kiladjian (Paris)

SESSION VIII – CALR Mutations in MPN Pathogenesis and Therapy
Chair: Jyoti Nangalia (Cambridge)

08:35-08:40	Introduction	Jyoti Nangalia (Cambridge)
08:40-08:55	Mechanisms of transformation by CALR mutation	Shannon Elf (Salt Lake City)
08:55-09:00	*Discussion*	
09:00-09:15	Pathogenicity and dependencies between mtCALR and MPL	Edwin Chen (Canterbury)
09:15-09:20	*Discussion*	
09:20-09:35	Mutant CALR as a therapeutic target	Isabelle Plo (Villejuif)
09:35-09:40	*Discussion*	
09:40-09:47	Brief oral communication *Discovery of JNJ-88549968, a novel, first-in-class CALRmutxCD3 T-cell engaging antibody for the treatment of myeloproliferative neoplasms*	Anna Kuchnio (Beerse)
09:47-09:50	*Discussion*	
09:50-09:57	Brief oral communication *Development of CAR-T cell therapy to selectively eliminate calreticulin-mutant neoplasms*	Alexandros Rampotas (London)
09:57-10:00	*Discussion*	
10:00-10:20	*Panel discussion*	

10:20-10:50 Coffee break

SESSION IX – Polycythemias
Chair: Jean-Jacques Kiladjian (Paris)

10:50-10:55	Introduction	Jean-Jacques Kiladjian (Paris)
10:55-11:10	Diagnosis and genetics of congenital erythrocytosis	Betty Gardie (Nantes)
11:10-11:15	*Discussion*	
11:15-11:30	Biology and clinical long-term outcome of JAK2-neg erythrocytosis	Stéphane Giraudier (Paris)
11:30-11:35	*Discussion*	

11:35-11:50	Future therapies for PV and ET	Claire Harrison (London)
11:50-11:55	*Discussion*	
11:55-12:02	Brief oral communication *Dominantly inherited PV-like erythrocytosis from a novel germline JAK2R715T gain-of function mutation present in 3 generations is corrected by Ropeg-IFN-a*	Josef Prchal (Salt Lake City)
12:02-12:05	*Discussion*	
12:05-12:35	*Panel discussion*	
12:35-12:45	***Closing Remarks***	

MEETING CLOSURE